Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorZhao Jun
About this trial
Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patient underwent a ct examination
Patient was confirmed to have pulmonary nodules
Patient has been determined to undergo surgical treatment
There are clear pathological results
Disqualifiers
Patient has no ct examination results
Refuse surgical treatment
Patient has no clear pathological diagnosis
Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
Trial population
The patient must be an inpatient of our hospital, have undergone ct examination and been confirmed as having pulmonary nodules, and have received surgical treatment with a clear pathological diagnosis. The medical records are complete and available for follow-up visits.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer
Biological/VaccineResearch on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Changes in peripheral blood immune indicators, differences in radiomics and clinicopathological characteristics
Time frame
Before surgery for patients with pulmonary nodules2
Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules.
Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules. The flow cytometry antibodies used to label activated T cells in this study include CD19, CD3, CD4, CD8. CD25, CD39, CD137,Foxp3, IFN γ, etc.
Time frame
Before surgery for patients with pulmonary nodulesSponsors and contacts
Click on the lead sponsor to view all of their trials.
Zhao Jun
Lead sponsor
The First Affiliated Hospital of Soochow University
Sponsor institution
Source ClinicalTrials.gov